In a recent interview with CNBC, Novavax’s chief executive officer (CEO) John Jacobs stated that some expected third-quarter sales from prior COVID vaccine purchase agreements might have been recognized in the second quarter. In the United States, the vaccine is marketed as Novavax COVID-19 Vaccine, Adjuvanted.ĭuring the quarter, the company recorded product sales of $285.2 million of product sales, which were significantly higher than the product sales of $55.5 million in the year-ago quarter. Novavax is currently marketing different versions of its protein-based COVID-19 vaccine - one marketed in partnership with the Serum Institute of India (Serum) under the trade name Covovax and another version produced by Novavax that is marketed under the trade name Nuvaxovid. In the year-ago quarter, the company reported revenues of $185.9 million. Revenues in the quarter amounted to $424.4 million, topping the Zacks Consensus Estimate of $257.6 million. In the year-ago quarter, the company posted a loss of $6.53 per share. This article first appeared on GuruFocus.Novavax, Inc. NVAX reported second-quarter 2023 earnings of 58 cents per share, which beat the Zacks Consensus Estimate of a loss of $1.24. ![]() GuruFocus Premium members can find more companies with strong GF Scores using the following screener link: GF Score Screen As value investors, it's crucial to consider these factors when making investment decisions. While Novavax Inc has made significant strides in the biotechnology industry, its current financial health and profitability metrics suggest that it may struggle to maintain its historical performance. Given the company's financial strength, profitability, and growth metrics, the GuruFocus Score Rating highlights the firm's unparalleled position for potential underperformance. Given its rating, Novavax Inc might be facing challenges in these areas. This score, rooted in Joseph Piotroski's nine-point scale, evaluates a firm's profitability, liquidity, and operating efficiency. With a Piotroski F-Score of 2, Novavax Inc's financial health appears concerning. Novavax Inc's low Profitability rank can also raise warning signals. This suggests that the company may face financial distress over the next few years. The company's Altman Z-Scoreis just -4.08, which is below the distress zone of 1.81. It's worth noting that the esteemed investor Benjamin Graham typically favored companies with an interest coverage ratio of at least five. This ratio highlights potential challenges the company might face when handling its interest expenses on outstanding debt. Novavax Inc has an interest coverage ratio of 0, which positions it worse than 0% of 380 companies in the Biotechnology industry. Novavax Inc's financial strength indicators present some concerning insights about the company's balance sheet health. Novavax develops product candidates geared toward all age demographics of the general population. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax Inc is a biotechnology company that develops vaccines. The GF Score ranges from 0 to 100, with 100 as the highest rank.īased on the above method, GuruFocus assigned Novavax Inc the GF Score of 67 out of 100, which signals poor future outperformance potential. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The stocks with a higher GF Score generally generate higher returns than those with a lower GF Score. ![]() The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |